These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 23836253

  • 1. [Dyspnoea, cough and B symptoms in a 40-year-old woman].
    Wolfensberger A, Benz R, Russi EW, Tinguely M, Keller C, Gerber B.
    Internist (Berl); 2013 Aug; 54(8):1011-5. PubMed ID: 23836253
    [Abstract] [Full Text] [Related]

  • 2. Mixed-type multicentric Castleman's disease developing during a 17-year follow-up of sarcoidosis.
    Awano N, Inomata M, Kondoh K, Satake K, Kamiya H, Moriya A, Ando T, Kumasaka T, Takemura T, Takeuchi K, Ikushima S.
    Intern Med; 2012 Aug; 51(21):3061-6. PubMed ID: 23124151
    [Abstract] [Full Text] [Related]

  • 3. Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases.
    Nagao A, Nakazawa S, Hanabusa H.
    J Hematol Oncol; 2014 Jan 17; 7():10. PubMed ID: 24438824
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Tocilizumab treatment of HHV8-positive/HIV-negative, multricentric plasma cell type Castleman's disease].
    Mûzes G, Csomor J, Sipos F.
    Magy Onkol; 2016 Nov 29; 60(4):328-332. PubMed ID: 27898752
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A case of multicentric Castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, tocilizumab.
    Higuchi T, Nakanishi T, Takada K, Matsumoto M, Okada M, Horikoshi H, Suzuki K.
    J Korean Med Sci; 2010 Sep 29; 25(9):1364-7. PubMed ID: 20808682
    [Abstract] [Full Text] [Related]

  • 8. Successful treatment of a patient with multicentric Castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody.
    Kawabata H, Kotani S, Matsumura Y, Kondo T, Katsurada T, Haga H, Kadowaki N, Takaori-Kondo A.
    Intern Med; 2013 Sep 29; 52(13):1503-7. PubMed ID: 23812199
    [Abstract] [Full Text] [Related]

  • 9. Sustained remission of multicentric Castleman disease in children treated with tocilizumab, an anti-interleukin-6 receptor antibody.
    Galeotti C, Boucheron A, Guillaume S, Koné-Paut I.
    Mol Cancer Ther; 2012 Aug 29; 11(8):1623-6. PubMed ID: 22638145
    [Abstract] [Full Text] [Related]

  • 10. Tocilizumab is effective for pulmonary hypertension associated with multicentric Castleman's disease.
    Taniguchi K, Shimazaki C, Fujimoto Y, Shimura K, Uchiyama H, Matsumoto Y, Kuroda J, Horiike S, Taniwaki M.
    Int J Hematol; 2009 Jul 29; 90(1):99-102. PubMed ID: 19554396
    [Abstract] [Full Text] [Related]

  • 11. A comorbid case of multicentric Castleman's disease and pulmonary hyalinising granuloma successfully treated with tocilizumab and corticosteroid.
    Takeuchi N, Arai T, Kitaichi M, Inoue Y.
    BMJ Case Rep; 2013 Sep 26; 2013():. PubMed ID: 24072826
    [Abstract] [Full Text] [Related]

  • 12. Successful treatment with tocilizumab for refractory anemia and slowly progressive renal glomerulosclerosis in multicentric Castleman disease: A case report.
    Sugawara E, Sato T, Amasaki Y, Katsumata K.
    Medicine (Baltimore); 2022 Feb 25; 101(8):e28941. PubMed ID: 35212301
    [Abstract] [Full Text] [Related]

  • 13. Clinical features and treatment of multicentric castleman's disease : a retrospective study of 21 Japanese patients at a single institute.
    Kawabata H, Kadowaki N, Nishikori M, Kitawaki T, Kondo T, Ishikawa T, Yoshifuji H, Yamakawa N, Imura Y, Mimori T, Matsumura Y, Miyachi Y, Matsubara T, Yanagita M, Haga H, Takaori-Kondo A.
    J Clin Exp Hematop; 2013 Feb 25; 53(1):69-77. PubMed ID: 23801137
    [Abstract] [Full Text] [Related]

  • 14. Multicentric Castleman's disease mimicking adult-onset Still's disease.
    Bianchi MM, Narváez J, Santo P, Ríos-Rodriguez V, de la Fuente D, Roig-Vilaseca D, Nolla JM.
    Joint Bone Spine; 2009 May 25; 76(3):304-7. PubMed ID: 19213588
    [Abstract] [Full Text] [Related]

  • 15. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease.
    Kawabata H, Tomosugi N, Kanda J, Tanaka Y, Yoshizaki K, Uchiyama T.
    Haematologica; 2007 Jun 25; 92(6):857-8. PubMed ID: 17550864
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman's disease.
    Arita Y, Sakata Y, Sudo T, Maeda T, Matsuoka K, Tamai K, Higuchi K, Shioyama W, Nakaoka Y, Kanakura Y, Yamauchi-Takihara K.
    Heart Vessels; 2010 Sep 25; 25(5):444-7. PubMed ID: 20676969
    [Abstract] [Full Text] [Related]

  • 18. Reversal of cardiomyopathy with tocilizumab in a case of HIV-negative Castleman's disease.
    Man L, Goudar RK.
    Eur J Haematol; 2013 Sep 25; 91(3):273-276. PubMed ID: 23786462
    [Abstract] [Full Text] [Related]

  • 19. Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease?
    Abid MB, Peck R, Abid MA, Al-Sakkaf W, Zhang Y, Dunnill GS, Staines K, Sequeiros IM, Lowry L.
    Hematol Oncol; 2018 Feb 25; 36(1):320-323. PubMed ID: 28401573
    [Abstract] [Full Text] [Related]

  • 20. Treatment of multicentric Castleman disease through combination of tocilizumab, lenalidomide and glucocorticoids: Case report.
    Cai S, Zhong Z, Li X, Wang HX, Wang L, Zhang M.
    Medicine (Baltimore); 2019 Nov 25; 98(46):e17681. PubMed ID: 31725610
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.